Stock Market Update - November 10, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. GLTO - Galecto, Inc.
Price: $17.25 | Change: +248.48% ($12.3)
GLTO saw an impressive 248.48% surge in its stock price around November 10, 2025. This dramatic climb was largely fueled by two significant announcements from Galecto, Inc.: a strategic acquisition and a substantial new funding round.
Galecto announced it had acquired Damora Therapeutics, a biotech company focused on developing treatments for certain blood cancers, significantly expanding Galecto's potential in this area. Simultaneously, the company secured nearly $285 million through a private investment. This substantial capital provides a financial runway into 2029 and is specifically earmarked to advance Damora's lead drug program through important early clinical trials by 2027, signaling strong investor confidence in the company's expanded pipeline.
2. MOVE - Movano Inc.
Price: $11.91 | Change: +149.69% ($7.14)
MOVE saw an incredible surge, jumping approximately 149.69% around November 11, 2025. This massive gain was primarily triggered by the announcement of an all-stock merger agreement with Corvex, Inc.
Under the definitive agreement, Movano will strategically transform into a pure-play AI infrastructure platform. The combined entity, which will operate under the new name "Corvex, Inc.," aims to capitalize on the rapidly growing demand for AI infrastructure at scale, leveraging Corvex's expertise in GPU-accelerated cloud computing for AI workloads.
To fuel this new direction, Corvex and Movano collectively secured $40.0 million from concurrent private placement financings. Interestingly, Movano Health will continue its existing medical device operations, including the FDA-cleared EvieMED Ring, indicating a dual focus for the original Movano business.
3. COGT - Cogent Biosciences, Inc.
Price: $32.46 | Change: +119.03% ($17.64)
COGT experienced a dramatic 119.03% gain, all thanks to a major announcement about its drug development. Cogent Biosciences reported highly encouraging late-stage clinical trial results for bezuclastinib, its lead drug candidate.
This breakthrough came from its Phase 3 PEAK trial for bezuclastinib, designed to treat an aggressive form of Gastrointestinal Stromal Tumors (GIST) that resists other treatments. The trial showed patients receiving bezuclastinib had significantly better outcomes, including a longer period without their disease worsening and more patients seeing their tumors shrink, compared to the standard therapy. These results far surpassed expectations, pointing to a potential new standard of care.
This impressive data positions bezuclastinib to potentially become the new standard of care for these GIST patients. The company plans to submit the drug for FDA approval in the first half of 2026. This significant clinical breakthrough and the anticipation of regulatory approval were the primary drivers behind the stock's dramatic ascent.
4. HKIT - Hitek Global Inc.
Price: $4.15 | Change: +89.50% ($1.96)
HKIT experienced a remarkable 89.50% surge on November 10, 2025, with shares of Hitek Global Inc. climbing from $2.19 to $4.15. This substantial single-day increase coincided with a very positive day for the broader market, as major US indices also saw significant gains, fueled by a tech rebound and wider optimism. While the company was due to release its earnings report around this time, a clear, company-specific reason for HKIT's dramatic ascent hasn't been explicitly detailed.
What makes HKIT's movement particularly interesting is the mixed bag of signals surrounding it. Despite the impressive jump, reports from mid-2025 highlighted challenging financial performance, including declining revenues and increased operating losses. Adding to the complexity, an analyst recommendation had been downgraded to "Hold," and a shareholder filed to sell a significant number of shares on the same day – typically considered negative news. This creates a fascinating scenario where the stock surged dramatically without an obvious positive catalyst to explain such a powerful move.
5. SELX - Semilux International Ltd. Ordinary Shares
Price: $1.05 | Change: +85.51% ($0.484)
SELX saw a remarkable 85.51% surge after filing its annual report on November 10, 2025. The big news wasn't just the report itself, but a major strategic shift announced within it.
Semilux International, previously focused on automotive components like LiDAR, is now diving headfirst into developing integrated AI-based control systems for unmanned aerial vehicles (UAVs), commonly known as drones. This pivot, targeting lucrative defense, industrial, and infrastructure sectors, has clearly captured investor imagination.
Despite the company reporting a wider net operating loss for 2024 and expecting more losses in the short term, the market's reaction suggests a strong belief in the long-term potential of this new direction into AI-powered drone technology. Investors appear to be valuing future prospects over current financials.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.